Global Urological Cancer Drugs Market Size, Status and Forecast 2022

October 2017 | 106 pages | ID: GC3303D79C8PEN
QYResearch

Abstracts

This report studies the global Urological Cancer Drugs market, analyzes and researches the Urological Cancer Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
This report focuses on the top players in global market, like

• Novartis
• Pfizer
• Johnson & Johnson
• AstraZeneca
• Astellas
• Bristol-Myers Squibb
• Abbott Laboratories
• Celgene Corporation
• Dendreon Corporation
• Ferring Pharmaceuticals
• GlaxoSmithKline
• Indevus Pharmaceuticals Inc
• Ipsen
• Roche Healthcare
• Sanofi S.A
• Tolmar Inc

Market segment by Regions/Countries, this report covers

• United States
• EU
• Japan
• China
• India
• Southeast Asia

Market segment by Type, Urological Cancer Drugs can be split into

• Tablets
• Injection

Market segment by Application, Urological Cancer Drugs can be split into

• Prostate Cancer
• Bladder Cancer
• Kidney Cancer
• Testicular Cancer
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

Global Urological Cancer Drugs Market Size, Status and Forecast 2022

1 INDUSTRY OVERVIEW OF UROLOGICAL CANCER DRUGS

1.1 Urological Cancer Drugs Market Overview
  1.1.1 Urological Cancer Drugs Product Scope
  1.1.2 Market Status and Outlook
1.2 Global Urological Cancer Drugs Market Size and Analysis by Regions
  1.2.1 United States
  1.2.2 EU
  1.2.3 Japan
  1.2.4 China
  1.2.5 India
  1.2.6 Southeast Asia
1.3 Urological Cancer Drugs Market by Type
  1.3.1 Tablets
  1.3.2 Injection
1.4 Urological Cancer Drugs Market by End Users/Application
  1.4.1 Prostate Cancer
  1.4.2 Bladder Cancer
  1.4.3 Kidney Cancer
  1.4.4 Testicular Cancer
  1.4.5 Other

2 GLOBAL UROLOGICAL CANCER DRUGS COMPETITION ANALYSIS BY PLAYERS

2.1 Urological Cancer Drugs Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
  2.2.1 Market Concentration Rate
  2.2.2 Product/Service Differences
  2.2.3 New Entrants
  2.2.4 The Technology Trends in Future

3 COMPANY (TOP PLAYERS) PROFILES

3.1 Novartis
  3.1.1 Company Profile
  3.1.2 Main Business/Business Overview
  3.1.3 Products, Services and Solutions
  3.1.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.1.5 Recent Developments
3.2 Pfizer
  3.2.1 Company Profile
  3.2.2 Main Business/Business Overview
  3.2.3 Products, Services and Solutions
  3.2.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.2.5 Recent Developments
3.3 Johnson & Johnson
  3.3.1 Company Profile
  3.3.2 Main Business/Business Overview
  3.3.3 Products, Services and Solutions
  3.3.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.3.5 Recent Developments
3.4 AstraZeneca
  3.4.1 Company Profile
  3.4.2 Main Business/Business Overview
  3.4.3 Products, Services and Solutions
  3.4.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.4.5 Recent Developments
3.5 Astellas
  3.5.1 Company Profile
  3.5.2 Main Business/Business Overview
  3.5.3 Products, Services and Solutions
  3.5.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.5.5 Recent Developments
3.6 Bristol-Myers Squibb
  3.6.1 Company Profile
  3.6.2 Main Business/Business Overview
  3.6.3 Products, Services and Solutions
  3.6.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.6.5 Recent Developments
3.7 Abbott Laboratories
  3.7.1 Company Profile
  3.7.2 Main Business/Business Overview
  3.7.3 Products, Services and Solutions
  3.7.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.7.5 Recent Developments
3.8 Celgene Corporation
  3.8.1 Company Profile
  3.8.2 Main Business/Business Overview
  3.8.3 Products, Services and Solutions
  3.8.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.8.5 Recent Developments
3.9 Dendreon Corporation
  3.9.1 Company Profile
  3.9.2 Main Business/Business Overview
  3.9.3 Products, Services and Solutions
  3.9.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.9.5 Recent Developments
3.10 Ferring Pharmaceuticals
  3.10.1 Company Profile
  3.10.2 Main Business/Business Overview
  3.10.3 Products, Services and Solutions
  3.10.4 Urological Cancer Drugs Revenue (Value) (2012-2017)
  3.10.5 Recent Developments
3.11 GlaxoSmithKline
3.12 Indevus Pharmaceuticals Inc
3.13 Ipsen
3.14 Roche Healthcare
3.15 Sanofi S.A
3.16 Tolmar Inc

4 GLOBAL UROLOGICAL CANCER DRUGS MARKET SIZE BY TYPE AND APPLICATION (2012-2017)

4.1 Global Urological Cancer Drugs Market Size by Type (2012-2017)
4.2 Global Urological Cancer Drugs Market Size by Application (2012-2017)
4.3 Potential Application of Urological Cancer Drugs in Future
4.4 Top Consumer/End Users of Urological Cancer Drugs

5 UNITED STATES UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

5.1 United States Urological Cancer Drugs Market Size (2012-2017)
5.2 United States Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

6 EU UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

6.1 EU Urological Cancer Drugs Market Size (2012-2017)
6.2 EU Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

7 JAPAN UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

7.1 Japan Urological Cancer Drugs Market Size (2012-2017)
7.2 Japan Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

8 CHINA UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

8.1 China Urological Cancer Drugs Market Size (2012-2017)
8.2 China Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

9 INDIA UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

9.1 India Urological Cancer Drugs Market Size (2012-2017)
9.2 India Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

10 SOUTHEAST ASIA UROLOGICAL CANCER DRUGS DEVELOPMENT STATUS AND OUTLOOK

10.1 Southeast Asia Urological Cancer Drugs Market Size (2012-2017)
10.2 Southeast Asia Urological Cancer Drugs Market Size and Market Share by Players (2016 and 2017)

11 MARKET FORECAST BY REGIONS, TYPE AND APPLICATION (2017-2022)

11.1 Global Urological Cancer Drugs Market Size (Value) by Regions (2017-2022)
  11.1.1 United States Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
  11.1.2 EU Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
  11.1.3 Japan Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
  11.1.4 China Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
  11.1.5 India Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
  11.1.6 Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2017-2022)
11.2 Global Urological Cancer Drugs Market Size (Value) by Type (2017-2022)
11.3 Global Urological Cancer Drugs Market Size by Application (2017-2022)

12 UROLOGICAL CANCER DRUGS MARKET DYNAMICS

12.1 Urological Cancer Drugs Market Opportunities
12.2 Urological Cancer Drugs Challenge and Risk
  12.2.1 Competition from Opponents
  12.2.2 Downside Risks of Economy
12.3 Urological Cancer Drugs Market Constraints and Threat
  12.3.1 Threat from Substitute
  12.3.2 Government Policy
  12.3.3 Technology Risks
12.4 Urological Cancer Drugs Market Driving Force
  12.4.1 Growing Demand from Emerging Markets
  12.4.2 Potential Application

13 MARKET EFFECT FACTORS ANALYSIS

13.1 Technology Progress/Risk
  13.1.1 Substitutes
  13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
  13.3.1 Economic Fluctuations
  13.3.2 Other Risk Factors

14 RESEARCH FINDING/CONCLUSION

15 APPENDIX

Methodology
Analyst Introduction
Data Source


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Urological Cancer Drugs Product Scope
Figure Global Urological Cancer Drugs Market Size (Million USD) (2012-2017)
Table Global Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Urological Cancer Drugs Market Share by Regions in 2016
Figure United States Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure EU Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Japan Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure China Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure India Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Southeast Asia Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Urological Cancer Drugs Market Share by Type in 2016
Figure Tablets Market Size (Million USD) and Growth Rate (2012-2017)
Figure Injection Market Size (Million USD) and Growth Rate (2012-2017)
Figure Global Urological Cancer Drugs Market Share by Application in 2016
Table Key Downstream Customer in Prostate Cancer
Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Prostate Cancer (2012-2017)
Table Key Downstream Customer in Bladder Cancer
Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Bladder Cancer (2012-2017)
Table Key Downstream Customer in Kidney Cancer
Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Kidney Cancer (2012-2017)
Table Key Downstream Customer in Testicular Cancer
Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Testicular Cancer (2012-2017)
Table Key Downstream Customer in Other
Figure Urological Cancer Drugs Market Size (Million USD) and Growth Rate in Other (2012-2017)
Table Urological Cancer Drugs Market Size (Million USD) by Players (2016 and 2017)
Figure Urological Cancer Drugs Market Size Share by Players in 2016
Figure Urological Cancer Drugs Market Size Share by Players in 2017
Table Novartis Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Novartis (2012-2017)
Figure Novartis Urological Cancer Drugs Business Revenue Market Share in 2016
Table Pfizer Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Pfizer (2012-2017)
Figure Pfizer Urological Cancer Drugs Business Revenue Market Share in 2016
Table Johnson & Johnson Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Johnson & Johnson (2012-2017)
Figure Johnson & Johnson Urological Cancer Drugs Business Revenue Market Share in 2016
Table AstraZeneca Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of AstraZeneca (2012-2017)
Figure AstraZeneca Urological Cancer Drugs Business Revenue Market Share in 2016
Table Astellas Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Astellas (2012-2017)
Figure Astellas Urological Cancer Drugs Business Revenue Market Share in 2016
Table Bristol-Myers Squibb Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Bristol-Myers Squibb (2012-2017)
Figure Bristol-Myers Squibb Urological Cancer Drugs Business Revenue Market Share in 2016
Table Abbott Laboratories Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Abbott Laboratories (2012-2017)
Figure Abbott Laboratories Urological Cancer Drugs Business Revenue Market Share in 2016
Table Celgene Corporation Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Celgene Corporation (2012-2017)
Figure Celgene Corporation Urological Cancer Drugs Business Revenue Market Share in 2016
Table Dendreon Corporation Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Dendreon Corporation (2012-2017)
Figure Dendreon Corporation Urological Cancer Drugs Business Revenue Market Share in 2016
Table Ferring Pharmaceuticals Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Ferring Pharmaceuticals (2012-2017)
Figure Ferring Pharmaceuticals Urological Cancer Drugs Business Revenue Market Share in 2016
Table GlaxoSmithKline Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of GlaxoSmithKline (2012-2017)
Figure GlaxoSmithKline Urological Cancer Drugs Business Revenue Market Share in 2016
Table Indevus Pharmaceuticals Inc Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Indevus Pharmaceuticals Inc (2012-2017)
Figure Indevus Pharmaceuticals Inc Urological Cancer Drugs Business Revenue Market Share in 2016
Table Ipsen Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Ipsen (2012-2017)
Figure Ipsen Urological Cancer Drugs Business Revenue Market Share in 2016
Table Roche Healthcare Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Roche Healthcare (2012-2017)
Figure Roche Healthcare Urological Cancer Drugs Business Revenue Market Share in 2016
Table Sanofi S.A Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Sanofi S.A (2012-2017)
Figure Sanofi S.A Urological Cancer Drugs Business Revenue Market Share in 2016
Table Tolmar Inc Basic Information List
Table Urological Cancer Drugs Business Revenue (Million USD) of Tolmar Inc (2012-2017)
Figure Tolmar Inc Urological Cancer Drugs Business Revenue Market Share in 2016
Table Global Urological Cancer Drugs Market Size (Million USD) by Type (2012-2017)
Figure Global Urological Cancer Drugs Market Size Share by Type in 2012
Figure Global Urological Cancer Drugs Market Size Share by Type in 2013
Figure Global Urological Cancer Drugs Market Size Share by Type in 2014
Figure Global Urological Cancer Drugs Market Size Share by Type in 2015
Figure Global Urological Cancer Drugs Market Size Share by Type in 2016
Figure Global Urological Cancer Drugs Market Size Share by Type in 2017
Table Global Urological Cancer Drugs Market Size (Million USD) by Application (2012-2017)
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2012
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2013
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2014
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2015
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2016
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2017
Table Top Consumer/End Users of Urological Cancer Drugs
Figure United States Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table United States Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure United States Urological Cancer Drugs Market Size Share by Players in 2016
Figure United States Urological Cancer Drugs Market Size Share by Players in 2017
Figure EU Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table EU Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure EU Urological Cancer Drugs Market Size Share by Players in 2016
Figure EU Urological Cancer Drugs Market Size Share by Players in 2017
Figure Japan Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Japan Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure Japan Urological Cancer Drugs Market Size Share by Players in 2016
Figure Japan Urological Cancer Drugs Market Size Share by Players in 2017
Figure China Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table China Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure China Urological Cancer Drugs Market Size Share by Players in 2016
Figure China Urological Cancer Drugs Market Size Share by Players in 2017
Figure India Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table India Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure India Urological Cancer Drugs Market Size Share by Players in 2016
Figure India Urological Cancer Drugs Market Size Share by Players in 2017
Figure Southeast Asia Urological Cancer Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Southeast Asia Urological Cancer Drugs Market Size (Million USD) by Players (2012-2017)
Figure Southeast Asia Urological Cancer Drugs Market Size Share by Players in 2016
Figure Southeast Asia Urological Cancer Drugs Market Size Share by Players in 2017
Figure Global Urological Cancer Drugs Market Size (Million USD) by Regions (2017-2022)
Table Global Urological Cancer Drugs Market Size (Million USD) by Regions (2017-2022)
Figure Global Urological Cancer Drugs Market Size Share by Regions in 2017
Figure Global Urological Cancer Drugs Market Size Share by Regions in 2022
Figure United States Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure EU Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure Japan Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure China Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure India Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure Southeast Asia Urological Cancer Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Table Global Urological Cancer Drugs Market Size (Million USD) by Type (2017-2022)
Figure Global Urological Cancer Drugs Market Size Share by Type in 2017
Figure Global Urological Cancer Drugs Market Size Share by Type in 2022
Table Global Urological Cancer Drugs Market Size (Million USD) by Application (2017-2022)
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2017
Figure Global Urological Cancer Drugs Market Size (Million USD) by Application in 2022